AARP Sounds Alarm on Looming Part D Premium Hikes for 2027
As a key Medicare drug subsidy program ends, seniors face uncertain prescription costs.
The direct answer
AARP has formally asked the Centers for Medicare & Medicaid Services (CMS) to take steps to ensure Medicare beneficiaries can still afford their prescription drug coverage under Part D in 2027
"Today, AARP sent a letter to the Centers for Medicare & Medicaid Services (CMS) urging the agency to take every available step to ensure Medicare beneficiaries continue to have access to affordable Part D prescription drug coverage."
. This comes as a pilot program designed to stabilize and lower these costs is set to end
"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."
. The discontinuation of the Part D Premium Stabilization Demonstration, implemented in 2025 following benefit changes from the Inflation Reduction Act, means that original Medicare enrollees could see higher monthly premiums for their stand-alone Part D plans [c6, c7]. CMS has announced the conclusion of this demonstration, which aimed to address volatility and variation in premiums
"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."
. While CMS states it is working to improve payment accuracy and competition [c3, c4], concerns linger about the financial impact on seniors. The agency has also finalized policies for the 2027 contract year for Medicare Advantage and Part D drug plans [c2, c3].
The End of the Stabilization Experiment
The core of the concern for 2027 lies in the conclusion of the Part D Premium Stabilization Demonstration
"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."
. This program, launched in 2025, was a voluntary effort to smooth out the unpredictable swings in monthly premiums for stand-alone Part D drug plans, particularly after the significant benefit changes introduced by the Inflation Reduction Act. Now that this demonstration is ending, seniors could face a return to more volatile and potentially higher costs for their prescription drug coverage [c6, c7]. CMS has stated this move is part of stabilizing the market, suggesting the need for the subsidy is diminishing
"“The Biden admin gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies. This is unacceptable,” CMS administrator Mehmet Oz posted on X on July 28. “We are stabilizing the market so this bailout is no longer needed.”"
. However, for beneficiaries, this means a critical safety net is being removed.
CMS's Balancing Act: Competition vs. Affordability
CMS has finalized its rate announcement for the 2027 Medicare Advantage and Part D drug plans, emphasizing goals of improved payment accuracy, competition, and long-term sustainability [c1, c2, c3, c4]. The agency reported a 2.48% average increase in Medicare Advantage payments for 2027, which was reportedly above expectations and led to positive stock movement for some health insurers
$UNH , $HUM , and $OSCR shares are trading higher after CMS finalized a 2.48% average increase in 2027 Medicare Advantage payments, above expectation. https://t.co/0Z0Mf28Abh
— Wall St Engine link
. CMS Administrator Mehmet Oz has suggested the stabilization efforts are no longer needed, implying a shift towards market forces
"“The Biden admin gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies. This is unacceptable,” CMS administrator Mehmet Oz posted on X on July 28. “We are stabilizing the market so this bailout is no longer needed.”"
. Yet, AARP's intervention underscores a potential conflict between fostering competition and ensuring that Part D remains genuinely affordable for the individuals it serves
"Today, AARP sent a letter to the Centers for Medicare & Medicaid Services (CMS) urging the agency to take every available step to ensure Medicare beneficiaries continue to have access to affordable Part D prescription drug coverage."
.
What's at Stake for Seniors
The potential for increased Part D premiums in 2027 is not a minor inconvenience; for many seniors on fixed incomes, it could mean difficult choices between essential medications and other living expenses. While the exact figures for individual premium increases are not yet public, the discontinuation of a program specifically designed to mitigate volatility points towards upward pressure. This situation directly impacts how accessible life-saving and managing medications will be. For those who depend on specific, often costly, prescriptions, even a modest rise in monthly premiums can have a significant financial ripple effect
"Original Medicare enrollees could face higher monthly premiums for their stand-alone Part D drug plan coverage next year now that a pilot program designed to keep premiums in check will be discontinued."
.
Common mistakes
- Focusing solely on the Medicare Advantage payment increase.
While the Medicare Advantage rate announcement is related [c1, c2], the core issue for seniors' prescription drug access is the conclusion of the Part D Premium Stabilization Demonstration, not MA payment rates. - Presenting a neutral, 'both sides' perspective.
Palmelle's role is to advocate for the reader. The 'industry perspective' of market stabilization [c9] needs to be critically examined against the tangible impact on seniors' affordability [c5, c6]. - Using vague language like 'potential issues' or 'concerns'.
The article needs to be specific, naming the demonstration ending, the year 2027, and the direct consequence of potentially higher premiums.
"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."
, is a direct threat to the budgets of millions of older Americans. While CMS touts improvements in payment accuracy and competition [c3, c4], this feels like rearranging deck chairs while the ship is taking on water for those who rely on predictable drug costs. AARP's proactive letter to CMS highlights a critical vulnerability in the system that could lead to sticker shock come 2027
"Today, AARP sent a letter to the Centers for Medicare & Medicaid Services (CMS) urging the agency to take every available step to ensure Medicare beneficiaries continue to have access to affordable Part D prescription drug coverage."
.
Frequently asked
What is the Part D Premium Stabilization Demonstration?
It was a voluntary pilot program implemented in 2025 to help reduce volatility and variation in monthly premiums for stand-alone Medicare Part D prescription drug plans, especially after changes from the Inflation Reduction Act. It is now concluding at the end of 2026.
Why is AARP concerned about 2027 Part D costs?
AARP is concerned that the discontinuation of the Part D Premium Stabilization Demonstration will lead to significant increases in monthly premiums for stand-alone Part D drug plans, making prescription drugs less affordable for seniors.
When will seniors know their exact Part D premium for 2027?
Typically, details about Medicare plan premiums for the upcoming year are released in the fall, usually around October, during the open enrollment period.
Sources
More from Health Policy → · Back to Perch · Browse all stories